In this study, we confirmed the presence of autoantibodies targeting the FHL1 protein in patients with IIM in 27% in the first available serum sample, but we also detected low levels of anti-FHL1 autoantibodies in patients with systemic sclerosis or SLE. This evidence concerns the gene FHL1 and systemic sclerosis.